TIL-Based Therapies Market, 2030 – ResearchAndMarkets.com


DUBLIN – (COMMERCIAL THREAD) – The report “TIL-based Therapies Market by Target Indications, Key Players and Key Geographies: Industry Trends and Global Forecast, 2021-2030” has been added to ResearchAndMarkets.com offer.

The “Til-based Therapies Market Global Forecast 2021-2030” report presents an in-depth study of the current market landscape and future potential of TIL therapies. The report highlights the efforts of industry players and academic organizations in this rapidly evolving segment of the biopharmaceutical industry.

The contemporary market for TIL-based therapies is characterized by a healthy and growing pipeline of nearly 60 product candidates; in fact, more than 28 of these therapies, including CCRT + TIL (Sun Yat-sen University), Lifileucel (Iovance Biotherapeutics), LTX-315 and TILs (Lytix Biopharma / Herlev Hospital) and IOV-2001 (Iovance Biotherapeutics), are at advanced stages of development.

The first TIL-based therapy, LN-145 under development by Iovance Biotherapeutics, is expected to be approved in 2022. Given the therapeutic benefits they have displayed so far, lucrative opportunities are likely to await the companies. with the capabilities required to develop and manufacture TIL-based therapies for the foreseeable future.

Over time, the clinical success of several TIL-based immunotherapy candidates has inspired many research groups around the world to focus their efforts on this relatively new class of cancer therapies. After 2014, interest in T cell therapies, including those involving TILs, increased exponentially.

In addition, a substantial body of evidence supporting the therapeutic benefits of TIL-based therapies has prompted the establishment of many strategic partnerships (focused on therapy development and clinical research) and has prompted several public and private investors to invest significant capital in innovative companies involved. in this domain.

Promising clinical results and ongoing technical developments, coupled with growing interest from biopharmaceutical developers, should enable the rapid progression of pipeline candidates to higher stages of development and eventually to the market. We are led to believe that the global TIL-based therapy market is poised to experience significant growth for the foreseeable future.

One of the main objectives of the report was to estimate the size of the existing market and identify potential growth opportunities for TIL-based therapies over the next decade. Based on several parameters, such as target consumer segments, region-specific adoption rates and expected prices of these products, we have developed informed estimates of the likely evolution of the market during the period. 2021-2030.

The report also includes probable sales forecasts for TIL-based therapies which are in intermediate or advanced stages of development.

Scope of the report

Among other elements, the report includes the following:

  • A detailed assessment of the current TIL-based therapies market landscape with respect to type of developer (industry / non-industry), stage of development (preclinical, phase I, phase I / II and phase II), therapeutic area (hematological cancer, solid tumor and others), popular target indications (melanoma, ovarian cancer, pancreatic cancer, head and neck cancer, sarcoma, colon cancer, acute myeloid leukemia, cancer of the stomach, chronic lymphocytic leukemia, cervical cancer, breast cancer and others), source of T cells (autologous and allogeneic), frequency of administration (single dose, multiple dose and split dose), segment of target patients (children, adults and elderly patients) and the type of treatment (monotherapy and combination therapy). In addition, the chapter provides details on the most active players (in terms of number of pipeline candidates) engaged in this field.

  • An analysis highlighting the main opinion leaders (KOLs) in this field. It includes a matrix 22 evaluating the relative experience of the preselected KOLs based on their contributions (in terms of involvement in various clinical studies) in this field, and a schematic representation of the world map, indicating the geographical location of the scientists / eminent researchers engaged in the development of therapies based on TIL.

  • Detailed profiles of therapies being evaluated at clinical stages (phase I / II or higher); each profile presents an overview of the therapy, its mechanism of action, current status of development, key clinical trial results, dosing regimen, and manufacturing information.

  • An overview of the main therapeutic areas targeted by TIL-based therapies. It also includes an assessment of the opportunity (in terms of revenue generating potential from sales of therapies) in the indications of oncological diseases.

  • An analysis of partnerships that have been established in the recent past, covering R&D agreements, licensing agreements (specific to technology platforms and product candidates), product development and commercialization agreements, manufacturing agreements , clinical trial collaborations, product supply management agreements, joint ventures and others.

  • An analysis of investments that have been made in companies that have proprietary products / technologies based on TIL. The different types of funding bodies reported in this area include seed funding, venture capital funding, capital raised through IPOs and subsequent public offerings, grants, and debt financing.

  • A case study on the manufacture of cell therapy products, highlighting the main challenges associated with the production of such therapies. In addition, it presents a detailed list of contractual service providers and in-house manufacturers engaged in this market.

  • An in-depth discussion of various factors that form the basis of cell therapy pricing. It presents different models / approaches that a pharmaceutical company can take, in order to decide the price of a therapy based on TIL.

  • A review of the key promotional strategies that have been adopted by the developers of marketed T cell therapies, namely KYMRIAH and YESCARTA.

For more information on this report, visit https://www.researchandmarkets.com/r/v69rxs


Leave A Reply